What is the appropriate pediatric dose of mycophenolate mofetil for an 11‑year‑old girl?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pediatric Dosing of Mycophenolate Mofetil for an 11-Year-Old Girl

For an 11-year-old girl, mycophenolate mofetil should be dosed at 600 mg/m² twice daily (up to a maximum of 1 g twice daily), with the specific dose determined by her body surface area. 1

Body Surface Area-Based Dosing Algorithm

The FDA-approved dosing strategy for pediatric patients aged 3 months to 18 years follows this approach: 1

  • BSA 1.25-1.5 m²: Administer 750 mg twice daily (1.5 g total daily dose) using capsules 1
  • BSA >1.5 m²: Administer 1 g twice daily (2 g total daily dose) using capsules or tablets 1
  • BSA <1.25 m²: Use oral suspension at 600 mg/m² twice daily 1

For an 11-year-old girl, the BSA typically falls in the range requiring either 750 mg or 1 g twice daily, depending on her height and weight.

Clinical Context Considerations

For Nephrotic Syndrome

If this patient has nephrotic syndrome (frequently relapsing or steroid-dependent), the KDIGO guidelines recommend starting at 1200 mg/m²/day divided into two doses, with a target MPA area under the curve >50 µg·h/mL if therapeutic drug monitoring is available. 2 The Ibadan consensus statement supports 600 mg/m² per dose twice daily with a minimum trial of 6 months to determine responsiveness, continuing for up to 24 months. 2

For Transplant Recipients

If this is a renal transplant patient, the standard pediatric dose of 600 mg/m² twice daily (maximum 2 g daily) applies, though research suggests this may result in higher-than-expected plasma levels and increased gastrointestinal side effects. 3, 4

Critical Monitoring Requirements

Monthly monitoring of white blood cell count is essential during mycophenolate mofetil therapy. 2 For nephrotic syndrome patients, CBC should be checked every 2-3 months. 2

Additional monitoring includes:

  • Complete blood count within 2-3 weeks after starting therapy 5
  • CBC 2-3 weeks after any dose increase 5
  • CBC every 3 months on stable dosing 5
  • If neutropenia develops (ANC <1.3 × 10³/µL), interrupt dosing or reduce the dose 1

Important Administration Details

Mycophenolate mofetil should be administered on an empty stomach, as food decreases peak concentration by 40%. 1 However, in stable patients, it may be given with food if necessary. 1

Avoid concurrent administration with antacids containing aluminum or magnesium, cholestyramine, iron supplements, or activated charcoal, as these inhibit absorption. 6

Duration of Therapy

The minimum treatment duration depends on indication:

  • Nephrotic syndrome: At least 6 months to assess response, up to 24 months total 2
  • Transplant maintenance: Typically indefinite 1

Most children relapse when mycophenolate mofetil is stopped prematurely, so continuation for at least 12 months is recommended before considering dose reduction. 2, 7

Common Pitfalls to Avoid

Gastrointestinal side effects occur more frequently in pediatric patients than adults, particularly at the 600 mg/m² twice daily dose. 3 If significant abdominal pain develops, consider switching to enteric-coated mycophenolic acid at equivalent doses (360 mg sodium mycophenolate = 500 mg mycophenolate mofetil). 2

Do not assume dose-proportional pharmacokinetics in children. Research demonstrates substantial interpatient variability (44%) and age-dependent dosing requirements, with younger children requiring higher doses per body surface area than adolescents. 8 Therapeutic drug monitoring should be considered if response is inadequate or side effects develop. 6, 7

For girls of childbearing potential, effective contraception is mandatory during treatment due to severe teratogenic risks (Category D in pregnancy). 2, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation.

Pediatric nephrology (Berlin, Germany), 2003

Guideline

Mycophenolate Mofetil Dosing and Treatment Guidelines for Systemic Sclerosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Mycophenolate Mofetil Dosing Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

MMF Dose Titration Decision

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.